ArticleCancer chemotherapy and pharmacology2026
Does mifamurtide affect the elimination of high-dose methotrexate in children with osteosarcoma?
Article in Cancer chemotherapy and pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe standard treatment protocol for osteosarcoma in children and adolescents includes neoadjuvant (pre-surgical) MAP chemotherapy (high-dose methotrexate [HD-MTX], high-dose doxorubicin, and cisplatin), full resection of the tumor, and then adjuvant post-surgical chemotherapy. In Europe, the immunostimulant mifamurtide is often added to the post-surgical MAP courses in patients with non-metastatic disease, based on evidence that it increases 6-year overall survival. It is unknown whether mifamurtide affects the elimination of HD-MTX.
methodsIn a retrospective single-center study, we reviewed clinical and laboratory parameters of children and adolescents with osteosarcoma who received the MAP protocol between 2012 and 2020. Patients were classified into two cohorts based on post-operative treatment exposure: an “HD-MTX + mifamurtide cohort” (patients with localized disease received pre-operatively HD-MTX and postoperatively HD-MTX with mifamurtide) and an “HD-MTX only” cohort (patients with metastatic disease received only HD-MTX pre- and post-operatively). For each HD-MTX dose, we calculated the area under the concentration curve (AUC24−72) from MTX plasma concentrations collected 24, 48, and 72 h after the beginning of the HD-MTX infusion. We compared AUC24−72 for HD-MTX doses before and after surgery in both cohorts.
resultsAmong 21 patients (mean age 16; 38% female), 11 were in the “HD-MTX + mifamurtide cohort”, and 10 in the “HD-MTX only” cohort. Among patients in the “HD-MTX + mifamurtide cohort”, the median MTX AUC24−72 in cycles before surgery (67.6 µmol*h/L; interquartile range, 51.2-131.4 µmol*h/L) was not significantly different from that in cycles after surgery with concomitant mifamurtide (84.5 µmol*h/L; IQR, 50.2-155.8 µmol*h/L; P = 0.61). Similarly, in patients in the “HD-MTX only” cohort, median AUC24−72 before and after surgery were comparable (P = 0.70).ConclusionsConcomitant mifamurtide therapy does not have a significant effect on methotrexate elimination after HD-MTX in children with osteosarcoma
Indexed as
Identifiers
41999402What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.